Tempus AI (NASDAQ:TEM) Trading Up 6.8% - Time to Buy?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) shares traded up 6.8% during mid-day trading on Monday . The company traded as high as $91.45 and last traded at $89.44. 25,048,636 shares changed hands during mid-day trading, an increase of 93% from the average session volume of 12,947,475 shares. The stock had previously closed at $83.75.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. William Blair downgraded shares of Tempus AI from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 12th. Stifel Nicolaus downgraded shares of Tempus AI from a "buy" rating to a "hold" rating and boosted their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Needham & Company LLC restated a "buy" rating and issued a $56.00 price target on shares of Tempus AI in a research report on Tuesday, January 14th. Bank of America boosted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a research report on Friday, December 13th. Finally, Guggenheim assumed coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a "buy" rating and a $74.00 price objective on the stock. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Tempus AI presently has an average rating of "Moderate Buy" and an average price target of $58.55.

Tempus AI Stock Performance

The company's fifty day moving average is $49.75 and its two-hundred day moving average is $51.44. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Buying and Selling

In other news, CAO Ryan M. Bartolucci sold 13,770 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $60.00, for a total transaction of $826,200.00. Following the sale, the chief accounting officer now owns 57,237 shares of the company's stock, valued at $3,434,220. This trade represents a 19.39 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew Polovin sold 51,504 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares in the company, valued at $10,431,543.15. The trade was a 17.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,583,467 shares of company stock worth $130,542,311.

Institutional Investors Weigh In On Tempus AI

Hedge funds and other institutional investors have recently made changes to their positions in the company. Operose Advisors LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $25,000. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI during the 3rd quarter worth approximately $30,000. Farther Finance Advisors LLC purchased a new position in shares of Tempus AI during the 4th quarter valued at approximately $34,000. Prestige Wealth Management Group LLC lifted its position in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after buying an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC purchased a new position in shares of Tempus AI during the 4th quarter valued at approximately $49,000. Institutional investors and hedge funds own 24.22% of the company's stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.